Skip to main content
TipRanks
Go Ultimate75% OFF

Aptamer Group Plc (APTA) AI Stock Analysis

12 Followers
GB:APTA

Aptamer Group Plc

(LSE:APTA)

Select Model
Rating:48Neutral
Price Target:GBX 0.37â–²(1.64% Upside)
Action:reiterated
Date:11/13/26

The overall score is constrained by persistent unprofitability and negative cash flows, which are the most significant risks. A recently strengthened balance sheet provides some stability, but technicals are mixed with an overbought RSI warning of a potential reversal despite short-term price momentum. The negative P/E ratio further underscores the lack of earnings.

Positive Factors
Balance Sheet StrengthThe sharp increase in equity and very low leverage provide a stronger financial cushion than in prior years. Limited debt reduces interest and refinancing pressure, giving Aptamer Group more flexibility to support operations while it works toward sustainable profitability.
Negative Factors
Persistent LossesDeeply negative profitability shows that current revenue is insufficient to cover the company’s operating cost base. Continued losses constrain internal reinvestment, weaken shareholder returns, and leave execution dependent on achieving substantially greater scale or reducing costs.

Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:APTA-59.44%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 12.66M
Dividend Yield
―
Average Volume (3M)
7.20M
Price to Earnings (P/E)
-12.2
Beta (1Y)
0.62
Revenue Growth
28.35%
EPS Growth
57.14%
Country
UK
Employees
34
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...

Aptamer Group Plc Financial Statement Overview

Summary

Financial performance is mixed. Revenue is growing and gross margins are improving, but the company remains deeply unprofitable with significant cash burn. The balance sheet is strong following recapitalization, providing a runway, but this is offset by weak income and cash flow scores.

Income Statement

45Neutral

Balance Sheet

72Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2022
Income Statement
Total Revenue1.54M1.54M1.20M860.00K4.04M1.75M
Gross Profit573.00K573.00K350.00K250.00K2.69M359.00K
EBITDA-2.60M-2.60M-2.28M-2.81M-2.20M-7.36M
Net Income-1.86M-1.86M-2.42M-2.96M-2.09M-7.84M
Balance Sheet
Total Assets7.18M7.18M2.83M2.77M11.52M2.75M
Cash, Cash Equivalents and Short-Term Investments4.36M4.36M1.06M870.00K6.69M234.00K
Total Debt170.00K170.00K491.00K817.00K1.31M1.08M
Total Liabilities1.44M1.44M1.45M1.88M3.47M2.45M
Stockholders Equity5.74M5.74M1.38M887.00K8.05M304.00K
Cash Flow
Free Cash Flow-2.30M-2.30M-2.01M-2.41M-2.79M-6.09M
Operating Cash Flow-2.13M-2.13M-2.00M-2.28M-2.38M-4.06M
Investing Cash Flow-253.00K-253.00K-92.00K-122.00K-418.00K-2.03M
Financing Cash Flow5.68M5.68M2.28M3.04M9.12M-365.00K

Aptamer Group Plc Technical Analysis

Technical Analysis SentimentPositive
Last Price0.36

Price Trends

50DMA0.32Positive
100DMA0.38Negative
200DMA0.53Negative

Market Momentum

MACD-0.00Negative
RSI67.70Neutral
STOCH67.62Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.32, and below the 200-day MA of 0.53, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 67.70 is Neutral, neither overbought nor oversold. The STOCH value of 67.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:APTA.

Aptamer Group Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:APTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 102.93M13.5967.81%7.61%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:APTAGB:APTA48NeutralGBP 12.66M-12.17-46.61%―28.35%57.14%
GB:AVCTGB:AVCT40UnderperformGBP 287.20M-6.47-1293.07%―――
GB:FABGB:FAB40UnderperformGBP 5.32M-4.29-97.87%―7.38%44.13%
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.29-451.74%―33.37%86.41%
GB:ARECGB:AREC33UnderperformGBP 35.11M155.003.75%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:APTAGB:AVCTGB:BVXPGB:OBDGB:FABGB:ARECDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:APTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:APTAAptamer Group Plc0.36-0.57-60.75%
GB:AVCTAvacta Group plc59.00-22.00-27.16%
GB:BVXPBioventix plc1970.00-17.97-0.90%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:FABFusion Antibodies Plc4.25-8.00-65.31%
GB:ARECArecor Therapeutics PLC77.503.504.73%

Aptamer Group Plc Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing

Aptamer Group lifts revenue and cash as licensing and pharma demand deepen

Positive
Oct 13, 2026

Aptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the year-end cash...

Business Operations and StrategyFinancial Disclosures

Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results

Positive
Oct 7, 2026

Aptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The comp...

Business Operations and Strategy

Aptamer Group Adds Cavendish as Joint Corporate Broker to Bolster Investor Reach

Positive
Aug 20, 2026

Aptamer Group plc has appointed Cavendish Capital Markets as joint corporate broker alongside Turner Pope Investments, strengthening its capital markets advisory team. The move aims to expand research coverage and deepen institutional engagement as t...

Business Operations and StrategyExecutive/Board Changes

Aptamer Group boosts director stakes and launches major incentive scheme

Positive
Aug 14, 2026

Aptamer Group has issued 12,936,511 new ordinary shares to remunerate Non-Executive Chairman Adam Hargreaves, via Pathcelerate Limited, and Non-Executive Director Tim Sykes, for services during the year to 30 June 2026. The share-based payments lift...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026